NexImmune Corp - רווח נקי למניה בארבעת הרבעונים האחרונים NEXI

The GURU.Markets system provides a chart of the rolling earnings per share YoY change, where -306.10 records a new level. NexImmune, Inc. (NEXI) dynamics rely on a flexible development culture for T-cell therapies. Monetization potential is created through partnerships with immunotherapy pharma behemoths. The stability of the business model is maintained by strict control over the transportation of specialized reagents via certified carriers.
NEXI (NexImmune): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period. This indicator allows for an assessment of cost management efficiency and business scaling rates. The trend of the rolling annual EPS YoY helps investors identify profitability deviations from industry averages. For NexImmune, Inc. (NEXI), such fluctuations reflect the financial pressure of development stages, while the diversification of the immunotherapy pipeline serves as a tool for profit stabilization.